Stem definition | Drug id | CAS RN |
---|---|---|
cardiac stimulants, pimobendan derivatives | 2171 | 74150-27-9 |
None
Property | Value | Reference |
---|---|---|
Vd (Volume of distribution) | 2 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 14 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.02 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 1.80 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Jan. 1, 1994 | YEAR INTRODUCED |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Cardiac failure | 92.98 | 49.38 | 28 | 237 | 76012 | 50528847 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Cardiac failure | 61.44 | 41.74 | 27 | 382 | 79260 | 29494858 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Cardiac failure | 132.07 | 41.06 | 52 | 731 | 132321 | 64365628 |
Renal impairment | 45.11 | 41.06 | 25 | 758 | 134992 | 64362957 |
None
Source | Code | Description |
---|---|---|
MeSH PA | D002316 | Cardiotonic Agents |
MeSH PA | D002317 | Cardiovascular Agents |
MeSH PA | D004791 | Enzyme Inhibitors |
MeSH PA | D010726 | Phosphodiesterase Inhibitors |
MeSH PA | D020011 | Protective Agents |
MeSH PA | D014665 | Vasodilator Agents |
CHEBI has role | CHEBI:35620 | vasodilator agents |
CHEBI has role | CHEBI:38147 | cardiotonic drugs |
CHEBI has role | CHEBI:50218 | phosphodiesterase inhibitors |
None
Species | Use | Relation |
---|---|---|
Dogs | Congestive heart failure caused by atrioventricular valvular insufficiency or dilated cardiomyopathy | Indication |
Dogs | Use with concurrent therapy for congestive heart failure | Indication |
Product | Applicant | Ingredients |
---|---|---|
Vetmedin | Boehringer lngelheim Animal Health USA Inc. | 1 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 10.86 | acidic |
pKa2 | 11.61 | acidic |
pKa3 | 4.76 | Basic |
pKa4 | 4.16 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Phosphodiesterase 3 | Enzyme | INHIBITOR | IC50 | 6.39 | CHEMBL | SCIENTIFIC LITERATURE | |||
Type-1 angiotensin II receptor | GPCR | IC50 | 4.77 | CHEMBL |
ID | Source |
---|---|
D01133 | KEGG_DRUG |
C0071071 | UMLSCUI |
CHEBI:32003 | CHEBI |
CHEMBL24646 | ChEMBL_ID |
DB11450 | DRUGBANK_ID |
C041648 | MESH_SUPPLEMENTAL_RECORD_UI |
4823 | PUBCHEM_CID |
5090 | INN_ID |
34AP3BBP9T | UNII |
1110783 | RXNORM |
017800 | NDDF |
None